L

Lexeo Therapeutics Inc
NASDAQ:LXEO

Watchlist Manager
Lexeo Therapeutics Inc
NASDAQ:LXEO
Watchlist
Price: 6.28 USD 3.97% Market Closed
Market Cap: 207.7m USD
Have any thoughts about
Lexeo Therapeutics Inc?
Write Note

Lexeo Therapeutics Inc
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Lexeo Therapeutics Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
L
Lexeo Therapeutics Inc
NASDAQ:LXEO
Research & Development
-$53.1m
CAGR 3-Years
-131%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Research & Development
-$7.9B
CAGR 3-Years
-4%
CAGR 5-Years
-9%
CAGR 10-Years
-10%
Gilead Sciences Inc
NASDAQ:GILD
Research & Development
-$5.5B
CAGR 3-Years
-4%
CAGR 5-Years
10%
CAGR 10-Years
-9%
Amgen Inc
NASDAQ:AMGN
Research & Development
-$5.8B
CAGR 3-Years
-7%
CAGR 5-Years
-8%
CAGR 10-Years
-3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Research & Development
-$3.5B
CAGR 3-Years
-7%
CAGR 5-Years
-15%
CAGR 10-Years
-14%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Research & Development
-$4.9B
CAGR 3-Years
-20%
CAGR 5-Years
-14%
CAGR 10-Years
-15%
No Stocks Found

Lexeo Therapeutics Inc
Glance View

Market Cap
207.7m USD
Industry
Biotechnology

Lexeo Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in New York City, New York and currently employs 53 full-time employees. The company went IPO on 2023-11-03. Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company. The firm has developed a number of disease-modifying gene therapy candidates to treat larger-rare cardiovascular diseases that have unmet need and no approved treatments that address the underlying genetic cause of the disease. These programs include: LX2006, LX2020, LX2021, and LX2022. LX2006 is a gene therapy candidate designed to intravenously deliver a functional frataxin (FXN), a gene for the treatment of Friedreich’s ataxia (FA) cardiomyopathy. LX2020 is a gene therapy candidate designed to intravenously deliver a functional PKP2 gene to cardiac muscle for the treatment of PKP2-ACM. LX2021 is a gene therapy candidate developing to intravenously deliver the coding sequence for the functional connexin 43 (Cx43) protein for a group of inherited cardiac muscle disorders. LX2022 delivers a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy (HCM).

LXEO Intrinsic Value
Not Available
L

See Also

What is Lexeo Therapeutics Inc's Research & Development?
Research & Development
-53.1m USD

Based on the financial report for Dec 31, 2023, Lexeo Therapeutics Inc's Research & Development amounts to -53.1m USD.

What is Lexeo Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 3Y
-131%

Over the last year, the Research & Development growth was -8%. The average annual Research & Development growth rates for Lexeo Therapeutics Inc have been -131% over the past three years .

Back to Top